Trial reportJournal for immunotherapy of cancer2019
Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer.
Trial report in Journal for immunotherapy of cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02692976 (A Randomized Phase IIa Study), which is not on this map. Cited by 73 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Phase IIa Study: Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients
Who cites it
73 citing papers in PubMed, 2 syntheses or guidelines pooled it, 110 citations in OpenAlex.
- Efficacy of Using Dendritic Cells in the Treatment of Prostate Cancer: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- The soldiers needed to be awakened: Tumor-infiltrating immune cells.Frontiers in genetics · 2022Pooled it
- Single-cell dissection of persistent tumor antigens in non-responders reveals opportunities for TAA-targeted vaccination after neoadjuvant therapy in esophageal squamous cell carcinoma.Journal for immunotherapy of cancer · 2026Trial
- Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial.Nature communications · 2024Trial
- Dendritic cell vaccination combined with carboplatin/paclitaxel for metastatic endometrial cancer patients: results of a phase I/II trial.Frontiers in immunology · 2024Trial
- Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial.Journal for immunotherapy of cancer · 2022Trial
- Immunological responses to adjuvant vaccination with combined CD1cOncoimmunology · 2022Trial
- Dendritic cell vaccines: Current research progress, challenges, and opportunities.Genes & diseases · 2026Review
- Feeder-free generation of functional dendritic cells from human pluripotent stem cells.Journal for immunotherapy of cancer · 2026Article
- Article
- Dendritic Cells: Origin, Classification, Development, Biological Functions, and Therapeutic Potential.MedComm · 2025Review
- Role of cDC2 in priming CD8Journal for immunotherapy of cancer · 2025Review
- Extemporaneous Compounding, Pharmacy Preparations and Related Product Care in the Netherlands.Pharmaceutics · 2025Review
- Synthetic Biology-Based Engineering Cells for Drug Delivery.Exploration (Beijing, China) · 2025Review
- Characterization of TLR9 responsiveness in cell subsets derived fromFrontiers in immunology · 2025Article
- Adoptive immune cell therapy for colorectal cancer.Frontiers in immunology · 2025Review
- Research progress of MUC1 in genitourinary cancers.Cellular & molecular biology letters · 2024Review
- Immunotherapy Vaccines for Prostate Cancer Treatment.Cancer medicine · 2024Review
- NY-ESO-1 antigen: A promising frontier in cancer immunotherapy.Clinical and translational medicine · 2024Review
- Plasmacytoid dendritic cells at the forefront of anti-cancer immunity: rewiring strategies for tumor microenvironment remodeling.Journal of experimental & clinical cancer research : CR · 2024Review
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClinical benefit of cellular immunotherapy has been shown in patients with castration-resistant prostate cancer (CRPC). We investigated the immunological response and clinical outcome of vaccination with blood-derived CD1c
methodsIn this randomized phase IIa trial, 21 chemo-naive CRPC patients received maximally 9 vaccinations with mature mDCs, pDCs or a combination of mDCs plus pDCs. DCs were stimulated with protamine/mRNA and loaded with tumor-associated antigens NY-ESO-1, MAGE-C2 and MUC1. Primary endpoint was the immunological response after DC vaccination, which was monitored in peripheral blood and in T cell cultures of biopsies of post-treatment delayed-type hypersensitivity-skin tests. Main secondary endpoints were safety, feasibility, radiological PFS (rPFS) and overall survival. Radiological responses were assessed by MRIs and contrast-enhanced
resultsBoth tetramer/dextramer-positive (dm
conclusionsImmunotherapy with blood-derived DC subsets was feasible and safe and induced functional antigen-specific T cells. The presence of functional antigen-specific T cells correlated with an improved clinical outcome.
trial registrationClinicalTrials.gov identifier NCT02692976, registered 26 February 2016, retrospectively registered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.